Bradycardia is defined as a heart rate of less than 60 beats per minute (bpm). It can be a physiological condition, as seen in athletes or during sleep, or pathological when caused by an alteration of the cardiac conduction system or by external factors affecting the regulation of heart rhythm.
Clinically, bradycardia may present as either intermittent or persistent and can have variable consequences depending on its severity. Milder forms are often asymptomatic, while more severe cases may impair organ perfusion and lead to symptoms such as syncope, dizziness, and fatigue.
Etiology
The causes of bradycardia are classified as intrinsic or extrinsic. Intrinsic causes arise from structural or functional alterations of the cardiac conduction system, whereas extrinsic causes are due to external factors that affect autonomic regulation or impulse generation.
Intrinsic causes:
Fibrotic degeneration of the conduction system: with aging, the conduction tissue undergoes progressive fibrosis, reducing the ability of the sinus node and atrioventricular (AV) node to generate and transmit electrical impulses effectively.
Ischemic heart disease: myocardial infarction, especially of the inferior wall, can compromise perfusion of the sinus or AV node, resulting in reduced heart rate or conduction blocks.
Infiltrative and degenerative diseases: conditions such as amyloidosis, sarcoidosis, and hemochromatosis may infiltrate myocardial tissue and impair impulse transmission.
Genetic disorders: some genetic mutations affecting cardiac ion channels can impair impulse generation, leading to sinus bradycardia or AV blocks.
Extrinsic causes:
Metabolic disorders: hypothyroidism decreases sinus node stimulation, while hyperkalemia and hypothermia impair myocardial cell function and slow impulse generation.
Bradycardic medications: beta-blockers, non-dihydropyridine calcium channel blockers, digoxin, and antiarrhythmics may reduce sinus node automaticity or slow AV conduction.
Increased vagal tone: conditions such as vasovagal syndrome or carotid sinus hypersensitivity may cause excessive vagal stimulation, inhibiting sinus node activity and slowing AV conduction.
Pathogenesis and Pathophysiology
Bradycardia may result from three main alterations in the cardiac conduction system:
Reduced sinus node automaticity: the sinus node is the primary cardiac pacemaker, and its activity depends on spontaneous cell depolarization. If this process is slowed by structural degeneration, metabolic disturbance, or excessive autonomic modulation, heart rate decreases.
Altered atrioventricular conduction: impulse transmission between atria and ventricles can be delayed or blocked at the AV node or His-Purkinje system. In first-degree blocks, the impulse is consistently delayed; in second-degree blocks, some impulses are interrupted; in third-degree blocks, transmission is completely impaired.
Autonomic dysfunction: excessive parasympathetic tone or reduced sympathetic activity can depress sinus node activity and slow AV conduction.
From a pathophysiological perspective, bradycardia leads to a reduction in cardiac output, which may be compensated by an increase in stroke volume. However, in more pronounced forms, inadequate systemic perfusion may impair cerebral and coronary blood flow, resulting in symptoms such as syncope and hypotension, and potentially cardiovascular collapse in severe cases.
Risk Factors and Prevention
Risk factors do not directly cause bradycardia but increase the likelihood of its development. They must be clearly distinguished from etiological causes and include predisposing conditions such as:
Advanced age: the risk of bradycardia increases with age due to progressive degeneration of the conduction system.
Family history of conduction disorders: certain types of bradycardia have a genetic predisposition and tend to occur more frequently in specific families.
Structural heart disease: patients with chronic heart failure, valvular disease, or left ventricular hypertrophy are more prone to develop conduction abnormalities.
Neurological disorders: conditions such as Parkinson’s disease or autonomic neuropathies can alter the regulation of heart rate.
Prevention relies on the management of modifiable risk factors, such as controlling cardiovascular diseases, monitoring autonomic function, and maintaining regular physical activity. In at-risk patients, cardiological follow-up is essential to detect potential conduction abnormalities.
Clinical Manifestations
The clinical presentation of bradycardia varies depending on severity, rate of onset, and the cardiovascular system’s compensatory capacity. In mild cases, bradycardia is often well tolerated and asymptomatic, especially in young individuals and athletes. However, when heart rate is significantly reduced, perfusion of vital organs may be compromised, leading to clear symptoms and signs.
The most common symptoms are related to reduced cerebral and muscular perfusion.
Patients may report persistent fatigue and tiredness due to inadequate oxygen delivery to the muscles.
Dizziness and near-syncope are frequent in more pronounced cases, especially when bradycardia leads to low blood pressure.
In more severe forms, particularly with advanced AV blocks, syncopal episodes with transient loss of consciousness may occur.
Additionally, patients may complain of exertional dyspnea and exercise intolerance, due to the heart’s limited capacity to increase cardiac output in response to higher metabolic demands.
Some individuals also report palpitations or a sensation of irregular heartbeat, particularly in intermittent bradycardia.
From a physical examination perspective, in marked bradycardia the physician may observe characteristic findings.
Reduced heart rate, often below 50 bpm in clinically relevant cases, is the most evident sign.
In cases of reduced cardiac output, arterial hypotension and altered mental status, such as confusion or poor concentration, may be observed.
In patients with impaired peripheral perfusion, pallor, cool skin, and acrocyanosis may be present. In cases where bradycardia is associated with heart failure, the physician may find dependent edema, jugular vein distention, and pulmonary rales, indicating systemic or pulmonary venous congestion.
Diagnosis
The diagnosis of bradycardia begins with the clinical finding of a reduced heart rate but requires a more in-depth evaluation to determine its nature, cause, and potential hemodynamic impact. The diagnostic process involves a stepwise approach, from physical examination to confirmation through ECG and specific testing.
Physical examination and clinical assessment
Pulse palpation and cardiac auscultation allow the detection of a heart rate below 60 bpm, which may be an isolated finding or indicate underlying dysfunction. However, to distinguish physiological from pathological bradycardia, clinical context must be assessed. A thorough history helps identify associated symptoms (such as syncope, dizziness, or fatigue), the use of bradycardic medications, and predisposing conditions such as hypothyroidism or autonomic dysfunction.
If the patient is asymptomatic and bradycardia is found in a young individual or athlete, it may represent a physiological variant. Conversely, symptomatic bradycardia or bradycardia associated with heart disease requires further investigations to determine its nature and clinical relevance.
Electrocardiogram (ECG)
The ECG is the first essential test to confirm bradycardia and identify its type. Depending on its characteristics, the ECG may reveal:
Sinus bradycardia: regular sinus rhythm with a heart rate <60 bpm.
Sinus pause: transient interruption of sinus node activity.
Sinoatrial block: delayed or absent transmission of the impulse from the sinus node to the atria.
Atrioventricular blocks: conduction disturbances between atria and ventricles, ranging from first-degree (prolonged PR interval) to third-degree (complete AV dissociation).
Prolonged ECG monitoring
If bradycardia is episodic or intermittent, resting ECG may not be sufficient to detect it. In such cases, prolonged monitoring is indicated using:
24–48 hour Holter ECG: useful to detect transient bradycardia and correlate rhythm abnormalities with symptoms.
Implantable loop recorder: indicated in patients with unexplained syncope and suspected paroxysmal bradycardia not documented with standard tests.
Functional tests and further evaluation
In patients where bradycardia is not clearly due to a structural conduction abnormality or when autonomic involvement is suspected, functional tests may be necessary to assess chronotropic response and autonomic control of heart rate. These tests are indicated in cases of syncope, exercise intolerance, or undocumented paroxysmal bradycardia.
Tilt test: used in patients with suspected vagal hypersensitivity or vasovagal syndrome to evaluate autonomic response to postural changes.
Exercise testing: performed in patients with exertional intolerance to assess chronotropic competence and differentiate between sinus node dysfunction and poor physiological adaptation.
Electrophysiological study (EPS): indicated in patients with suspected advanced sinus node dysfunction or high-degree AV blocks, especially when considering pacemaker implantation.
Laboratory tests
If no obvious cause of bradycardia is identified, laboratory investigations are performed to rule out reversible conditions:
Thyroid hormones (TSH, FT4): to detect potential hypothyroidism.
Electrolyte panel: to identify hyperkalemia or abnormalities in sodium and calcium levels.
Cardiac enzymes (troponin, CK-MB): in case of suspected myocardial ischemia.
A comprehensive clinical and instrumental assessment allows differentiation between physiological and pathological bradycardia and helps identify patients requiring treatment and specific follow-up.
Treatment and Prognosis
The treatment of bradycardia depends on the underlying cause and the presence of clinically relevant symptoms. In some cases, bradycardia may not require any intervention, whereas in symptomatic forms or those posing a risk of hemodynamic compromise, specific treatment may be necessary.
Therapeutic approach:
Withdrawal or adjustment of medication: in patients taking bradycardic drugs, reducing the dose or discontinuing treatment can improve heart rate.
Correction of metabolic disturbances: treating hypothyroidism, hyperkalemia, or hypothermia may restore normal heart rate in cases due to metabolic imbalances.
Pharmacological stimulation: in acute settings, drugs such as atropine (a muscarinic antagonist) can temporarily increase heart rate.
Pacemaker implantation: indicated in severe symptomatic bradycardia, advanced AV blocks, or in patients with sinus node dysfunction not responsive to other therapies.
The prognosis of bradycardia depends on its cause and the timeliness of treatment. Benign forms, such as sinus bradycardia in athletes, have no impact on survival. However, in untreated severe bradycardia, the risk of syncope, heart failure, and sudden death may be significant.
Complications
If not adequately treated, bradycardia can lead to potentially serious complications, especially in patients with underlying heart disease. The main complications include:
Syncope and falls: reduced cerebral perfusion may cause sudden syncopal episodes, increasing the risk of fall-related trauma.
Heart failure: in severe forms, reduced cardiac output may lead to decompensated heart failure.
Arrhythmias: marked bradycardia may favor the onset of ventricular arrhythmias, increasing the risk of sudden cardiac death.
Chronic hypotension: in persistent bradycardia, blood pressure may remain chronically low, leading to symptoms of organ hypoperfusion.
Early recognition of pathological bradycardia and appropriate treatment are essential to prevent complications and improve patients’ quality of life.
References
Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal. 2018;39(21):1883-1948.
Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay. Journal of the American College of Cardiology. 2019;74(7):932-987.
Alboni P, Alboni M. Vasovagal syncope as a mythological syndrome: a critical review of a wide-spread entity. Journal of Arrhythmia. 2022;38(1):76-84.
Wang TJ, Larson MG, Levy D, et al. Impact of Obesity on Electrocardiographic Left Ventricular Hypertrophy. Journal of the American College of Cardiology. 2004;43(6):1046-1051.
Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on the Evaluation of Syncope. Circulation. 2008;118(8):850-878.
Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. Circulation. 2017;136(5):e60-e122.
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603.
Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation. 2008;117(21):e350-e408.
Semelka M, Gera J, Usman S. Sick sinus syndrome: a review. American Family Physician. 2013;87(10):691-696.
